Scarica l'app Stockscreener
76.35
1.85%
1.39
Pre-mercato:
76.09
-0.26
-0.34%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DXCM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$74.96
Aprire:
$75.56
Volume 24 ore:
3.54M
Relative Volume:
0.63
Capitalizzazione di mercato:
$29.46B
Reddito:
$4.82B
Utile/perdita netta:
$930.40M
Rapporto P/E:
32.65
EPS:
2.3381
Flusso di cassa netto:
$1.43B
1 W Prestazione:
+5.48%
1M Prestazione:
+1.30%
6M Prestazione:
+8.68%
1 anno Prestazione:
-8.42%
Intervallo 1D:
$74.58
$76.42
Intervallo di 1 settimana:
$71.25
$76.42
Portata 52W:
$54.11
$89.98
Dexcom Inc Stock (DXCM) Company Profile
Nome
Dexcom Inc
Settore
Industria
Telefono
(858) 200-0200
Indirizzo
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
76.35 | 29.46B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
92.11 | 160.44B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
331.45 | 127.06B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.57 | 106.97B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
44.65 | 66.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
91.79 | 52.85B | 6.30B | 1.07B | 1.09B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-24 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2026-01-12 | Downgrade | Barclays | Equal Weight → Underweight |
| 2025-12-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Iniziato | Evercore ISI | In-line |
| 2025-10-21 | Ripresa | Stifel | Buy |
| 2025-09-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Iniziato | Argus | Buy |
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-02-03 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Iniziato | Redburn Atlantic | Neutral |
| 2024-03-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2023-01-26 | Iniziato | Wolfe Research | Outperform |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-15 | Iniziato | Bernstein | Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-28 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2021-01-06 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-02 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Reiterato | Piper Sandler | Overweight |
| 2020-05-14 | Iniziato | Wells Fargo | Equal Weight |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-11-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-10-23 | Iniziato | Stifel | Buy |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-19 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-09-12 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Reiterato | Canaccord Genuity | Buy |
| 2018-07-02 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
| 2018-05-03 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-04 | Iniziato | Goldman | Sell |
| 2018-04-04 | Iniziato | Guggenheim | Neutral |
| 2018-03-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Reiterato | Wedbush | Outperform |
Mostra tutto
Dexcom Inc Borsa (DXCM) Ultime notizie
Dexcom receives Health Canada authorization for G7 15 Day CGM By Investing.com - Investing.com Nigeria
Global Blood Glucose Monitoring System Market Size to Reach USD 39.4 Billion by 2035 | Growing at 8.9% CAGR | Industry Trends, Market Share & Forecast – Custom Market Insights - GlobeNewswire Inc.
Dexcom (DXCM) Gains Health Canada Approval for New CGM System - GuruFocus
Dexcom receives Health Canada authorization for G7 15 Day CGM - Investing.com UK
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
LE DEXCOM G7 15 JOURS A OBTENU L’AUTORISATION DE SANTÉ CANADA : UNE DURÉE DE PORT PROLONGÉE ET UNE CONTINUITÉ AMÉLIORÉE POUR LES ADULTES CANADIENS VIVANT AVEC LE DIABÈTE - The Joplin Globe
Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes - Dexcom Investor Relations
Here's why you should retain DexCom stock in your portfolio - MSN
Dexcom stock holds steady on its glucose monitor business - Ad Hoc News
DEXCOM INC (NASDAQ:DXCM) Screens as a Strong Growth Stock with Favorable Technical Setup - ChartMill
Is DexCom (DXCM) Undervalued Following Its Investor Day Sentiment Shift? - Yahoo Finance
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - AOL.com
DexCom Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Dexcom to release Q2 2026 earnings on July 30, 2026 - scanx.trade
Is DexCom’s (DXCM) Sensor Recall Exposing Deeper Questions About Its Quality Controls and Data Systems? - Sahm
Investors’ Confidence in DexCom (DXCM) Rises as Growth Outlook Reassured - Yahoo Finance
Press Release: Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 P.m. Eastern Time - Moomoo
Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time - Business Wire
Dexcom Inc. focuses on continuous glucose monitoring as investors track long-term growth - AD HOC NEWS
Dexcom Inc. focuses on continuous glucose monitoring growth. Long-term diabetes trends support the b - Ad-hoc-news.de
Dexcom (DXCM) Executive Chair sells 26,756 shares in 10b5-1 open-market trade - Stock Titan
Dexcom Inc. updates its diabetes tech platform as investors track long-term growth - AD HOC NEWS
Devon Energy Corp focuses on U.S. shale production as investors track cash returns - AD HOC NEWS
DexCom (NASDAQ: DXCM) Form 144 lists proposed sale of 26,756 shares - Stock Titan
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now - Barchart.com
DXCMDexcom Inc Latest SEC Filings - Finviz
Earnings Preview: What To Expect From DexCom's Report - Yahoo Finance
Dexcom G7 Continuous Glucose Monitor from Dexcom Inc.smaller sensor and direct-to-watch in the US - AD HOC NEWS
JPMorgan (NYSE: JPM) offers autocall contingent-interest notes tied to DexCom stock - Stock Titan
DexCom shareholders urged to act as law firm pr... - Pluang
Patient Monitoring Stocks Q1 Results: Benchmarking DexCom (NASDAQ:DXCM) - Yahoo Finance
Securities Fraud Class Action Filed Against DexCom, Inc. (DXCM) – - The National Law Review
DXCM News | DEXCOM INC (NASDAQ:DXCM) - ChartMill
DexCom Inc (DXCM) Stock Up 3.5% and Still Undervalued -- GF Scor - GuruFocus
DexCom Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
DexCom: The Growth Thesis Still Needs To Be Proven - Seeking Alpha
Dexcom G7 CGM sensoraccessory that makes stacking multiple days easier - AD HOC NEWS
Enterprise value to revenue forward of DexCom, Inc. – NASDAQ:DXCM - TradingView
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating DexCom, Inc. (DXCM) And Encourages Investors to Connect - The National Law Review
Devon Energy Wolfcamp development programshale wells drive long-term output - AD HOC NEWS
Is DexCom Inc (DXCM) a Bargain After 3.8% Drop? GF Value Says Un - GuruFocus
DexCom Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Dexcom G7 Professional from Dexcom Inc.Clinic-first CGM for short-term wear - AD HOC NEWS
DXCM ALERT: Securities Fraud Class Action Launched Against DexCom, Inc.December 26, 2025 Deadline - The National Law Review
Price to sales forward of DexCom, Inc. – NASDAQ:DXCM - TradingView
Enterprise value to EBITDA forward of DexCom, Inc. – SIX:DXCM - TradingView
Price to sales forward of DexCom, Inc. – SIX:DXCM - TradingView
Price to book forward of DexCom, Inc. – NASDAQ:DXCM - TradingView
Redefining CGM for people with type 2 diabetes: Dexcom announces Dexcom Flex in Germany - MSN
Price to earnings forward of DexCom, Inc. – NASDAQ:DXCM - TradingView
Dexcom Inc Azioni (DXCM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.94%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):